Dismiss this notification
PatientsLikeMe would like to remind you that your browser is out of date and many features of the website may not function as expected.
Please update your browser
for more security and a better experience.
NCT01227902 is an open-label, flexible dose study of retigabine immediate release (IR) as adjunctive therapy to specified monotherapy antiepileptic treatments in adults with partial-onset seizures. Other study IDs include: 113905 and IR.
Advice & Tips:
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.
Cost:
< $25 monthly
Aug 20, 2010
(Started Jan 09, 2000)
Effectiveness
Major
(for epilepsy)
Side effects
Moderate
Adherence
Always
Burden
Not at all hard to take
Dosage:
900 mg
Daily
Advice & Tips:
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.
Cost:
< $25 monthly
0helpful marks
Last updated:
Showing 1 of 1 patient evaluation for Epilepsy Phase 3 Study Retigabine IR
